Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-033 in advanced solid tumors
NCT05367232Phase 1Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICP-033 in solid tumor (advanced stage), sponsored by InnoCare Pharma. Primary endpoints: Incidence and severity of adverse events (AEs), Dose-Limiting Toxicities and 2 more. Started Feb 2022; status: recruiting.
02
Drugs
ICP-033
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05367232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367232.